Groupe d'Etude en Oncologie du Quebec

Title	Capturing Canadian Real-World Data for AML Chemotherapy Ineligible Patients on Venetoclax
Protocole ID	LIVEN (P23-363)
ClinicalTrials.gov ID	NCT05424562
Cancer Type(s)	Acute Myeloid Leukemia
Phase	Other
Stage
Study Type	Other
Drug
Institution	CENTRE UNIVERSITAIRE DE SANTE MCGILL SITE GLEN 1001 boul. Décarie , Montréal, QC, H4A 3J1
City
Principal Investigator	Dr. John Storring
Coordinator	Judit Kokai 438-888-1582
Status	Recruiting
Activation Date	27-01-2023
Eligibility Criteria	Diagnosis of Acute Myeloid Leukemia (AML). Ineligible for intensive chemotherapy, determined by the physician's assessment of age, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), comorbidities, regional guidelines, and institutional practice. Participant for whom the physician has decided to initiate venetoclax treatment in accordance with the local label. The decision to treat with venetoclax is made by the physician prior to any decision to approach the participant to participate in this study.
Exclusion Criteria	Participation in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.

Groupe d'étude en oncologie du Québec